Vanda Pharmaceuticals (VNDA) Earnings Date & Reports

Key Takeaways

• Q2 2026 results are expected around July 29–30, 2026, with consensus revenue estimates ranging between $61 million and $63 million and consensus EPS (earnings per share) of approximately -$0.58 to -$0.60.
• NEREUS (tradipitant), launched in Q1 2026, enters its first full quarter of contribution, and investors will closely scrutinize initial uptake through the company's direct-to-consumer platform.
• Fanapt remains the commercial engine, with Q1 total prescriptions up 32% year-over-year; sustaining that momentum is critical to the top-line narrative.
• Cash reserves fell by $61.5 million in Q1 to $202.3 million, and the rate of cash consumption is a central concern heading into the second half of 2026.
• Multiple pipeline catalysts loom beyond Q2, including the BYSANTI commercial launch, two Phase III readouts, and the imsidolimab PDUFA (Prescription Drug User Fee Act) date in December.

Earnings Context and Why It Matters

Vanda Pharmaceuticals (NASDAQ: VNDA) enters its second-quarter 2026 report at a pivotal moment. The company is transitioning from a largely single-product narrative into a multi-product biopharmaceutical story, following the February 2026 FDA (U.S. Food and Drug Administration) approval of BYSANTI (milsaperidone) and the Q1 commercial launch of NEREUS. However, the Q1 2026 print disappointed — revenue of $51.7 million and a loss per share of $0.82 both missed consensus — and the stock has drifted approximately 13% lower over the past month. With operating expenses running above $100 million per quarter and cash declining, the Q2 update will be scrutinized for signals on whether the product portfolio expansion is translating into meaningful revenue growth or merely adding cost layers.

Earnings Expectations

Wall Street consensus for Vanda's second quarter of 2026 points to revenue in the range of $61 million to $63 million, which would represent year-over-year growth of roughly 17% to 20% from the $52.6 million recorded in Q2 2025. On the bottom line, analysts expect a net loss per share between $0.52 and $0.60, compared with a loss of $0.46 per share in the same quarter last year. The wider expected loss reflects the elevated operating cost base tied to the ongoing commercialization of Fanapt in bipolar I disorder, preparation for the BYSANTI launch expected in the second half of 2026, and the initial marketing spend behind the NEREUS direct-to-consumer platform.

Investors will pay particular attention to NEREUS net product sales, for which management introduced full-year 2026 guidance of $10 million to $30 million during the Q1 call. Given that this range was described by CFO Kevin Moran as "more modeling" than data-driven, any early revenue signal — however modest — will help validate or challenge the launch trajectory. Fanapt remains the linchpin: Q1 net sales of $29.6 million (up 26% year-over-year) were encouraging, and management guided to $150 million to $170 million for the full year. The Q2 figure will need to show sequential reacceleration from the seasonally soft Q1 to keep that target credible. HETLIOZ, meanwhile, is expected to continue declining as generic competition persists.

AI Screener

For investors seeking to identify opportunities beyond individual earnings reports, Tickeron's AI Screener offers a powerful AI-driven stock and ETF discovery tool designed to filter thousands of equities based on technical patterns, fundamental metrics, volatility profiles, and proprietary AI signals. Users can customize searches by industry, market capitalization, technical indicators, price patterns, and performance benchmarks to surface trade ideas, breakout candidates, and trending stocks far more efficiently than through manual screening. Whether monitoring pre-earnings setups or scanning for post-report momentum, the AI Screener helps traders and investors stay ahead of market-moving developments.

Market Reaction and Investor Sentiment

Sentiment heading into Vanda's Q2 report appears cautious. The stock closed at $5.22 on July 27, 2026, near the lower end of its 52-week range of $4.14 to $9.94, and down roughly 41% year-to-date. The May 2026 Q1 earnings miss triggered a sharp -14% single-day decline, and the shares have continued to drift lower — falling from above $6.00 in early July to the low-$5.00 range in recent sessions. The analyst community maintains a split view: four analysts tracked by major aggregators carry an average "Buy" rating with a consensus 12-month price target of approximately $14, implying significant potential upside, yet the market's pricing reflects deep skepticism about the path to profitability. Key risk factors include faster-than-expected cash consumption, a slower NEREUS ramp, and the persistent drag from HETLIOZ generic erosion. A revenue miss or disappointing NEREUS metrics could amplify downside pressure, while a beat paired with encouraging launch commentary could stabilize the recent slide.

Forward Outlook and Key Factors to Monitor

Beyond the Q2 headline numbers, investors should focus on several forward-looking indicators that will shape Vanda's trajectory through year-end 2026 and into 2027.

The NEREUS launch ramp will be dissected for any quantitative color — prescriptions, website traffic, repeat orders, or geographic uptake patterns. As the first new prescription therapy for motion-sickness-related vomiting in more than 40 years, the total addressable market is substantial, but the direct-to-consumer, cash-pay model at approximately $85 per capsule (a roughly 65% discount to the wholesale acquisition cost) represents an untested commercial strategy for Vanda. Early traction or lack thereof will heavily influence confidence in the $10 million to $30 million full-year revenue target.

The BYSANTI commercial launch, planned for the second half of 2026, represents another major catalyst. Approved for both bipolar I disorder and schizophrenia, BYSANTI benefits from data exclusivity through February 2031 and patent protection into 2044. Management has signaled that BYSANTI may command a favorable net price relative to Fanapt, making it a potentially higher-margin contributor once launched. Any update on launch timing or payer discussions will be noteworthy.

On the pipeline front, three events are approaching that could materially alter Vanda's risk-reward profile: the Thetis Phase III study of NEREUS for GLP-1 (glucagon-like peptide-1) receptor agonist-related vomiting (results expected in 2026), the Phase III study of VQW-765 for social anxiety disorder (results expected by year-end 2026), and the December 12, 2026 PDUFA target action date for imsidolimab in generalized pustular psoriasis. Positive readouts could validate the broader pipeline strategy and attract renewed investor interest.

Finally, cash management remains the overarching concern. With $202.3 million on hand as of March 31, 2026, and quarterly operating expenses north of $100 million, investors will closely monitor whether the revenue trajectory can begin to close the gap. Any commentary on cash runway, spending discipline, or potential financing strategies will carry significant weight in the post-earnings narrative.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations